Načítá se...

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Peyser, Alexandra, MacHardy, Nathaniel, Tarapore, Freya, MacHardy, Jacqueline, Powell, Leslie, Gipson, Debbie S, Savin, Virginia, Pan, Cynthia, Kump, Theresa, Vento, Suzanne, Trachtman, Howard
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2010
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://ncbi.nlm.nih.gov/pubmed/20113498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-11-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!